Intellia Therapeutics: FDA Clearance of its Systemically Administered NDA of NTLA-2001 in Global Phase 3 Trial

Intellia Therapeutics' NTLA-2001
Intellia Therapeutics' NTLA-2001 is the first-ever investigational in vivo CRISPR-based gene editing therapy cleared to enter late-stage clinical development.  

Today, October 18, 2023, Intellia Therapeutics (NTLA) announced that the U.S. Food and . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.